Stock OCS OCULIS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Oculis Holding AG

Equities

OCS

CH1242303498

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-06-04 pm EDT 		5-day change 1st Jan Change
11.95 USD +0.84% Intraday chart for Oculis Holding AG +1.62% +6.41%
May. 30 Oculis Holding AG Announces Board and Committee Appointments CI
May. 30 Oculis Holding AG announced a financing transaction CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
OCULIS HOLDING AG Stock Oculis Holding AG
+6.41% 495M -
MODERNA, INC. Stock Moderna, Inc.
+51.85% 57.87B
B-
LONZA GROUP AG Stock Lonza Group AG
+41.42% 40.25B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 39.94B
B
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 28.54B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 26.4B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 19.33B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 12.4B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 12.23B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 12.2B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-
  1. Stock Market
  2. Equities
  3. OCS Stock
  4. Ratings Oculis Holding AG